Transforming Cancer Care with Cutting-Edge CAR T Cell Therapies
“At VectorGene, we provide a turnkey solution for hospitals looking to establish CAR T-cell therapy labs. From training your staff, sourcing the equipment, setting up the lab and developing the infusion center, we handle everything.”
“Let's collaborate to bring the future of cancer treatment to your hospital today."
Key Features
-
State-of-the-art CAR T cell vectors
Our CAR T cell vectors are precision-engineered using the latest advancements in biotechnology to ensure unparalleled efficacy and safety in cancer treatments.
-
Seamless technology transfer
Our company specializes in seamless CAR T cell therapy technology transfer, ensuring efficient, reliable, and scalable solutions for advanced cell-based treatments.
-
Comprehensive training program
We provide comprehensive training programs tailored for clinicians and technicians, focusing on mastering CAR T cell therapy protocols, from preparation to patient care and infusion management.
Products
-
CD19 Vectors
Demonstrates proven efficacy in B-cell malignancies, supported by extensive research and clinical application, contributing to improved treatment outcomes for patients.
-
CD22 Vectors
Specifically designed to overcome resistance in B-cell therapies, backed by research and clinical success, ensuring enhanced outcomes for challenging cases.
-
BCMA Vectors
Advanced vector solution specifically engineered for treating multiple myeloma, demonstrating effectiveness through clinical success and supporting the fight against challenging cancers.
Comprehensive Solutions for CAR T-Cell Therapy Implementation
Supply of high-quality CAR T cell therapy vectors.
Technician training: Vector preparation, storage, and handling.
Clinician training: Patient selection, therapy administration, and post-infusion management.
Ongoing support: Clinical troubleshooting and updates.
Are you ready to revolutionize cancer treatment?
At VectorGene, we're not just manufacturing CAR T-cell therapies; we're empowering cancer centers to build their own CAR T labs. Please write to us at care@beijingbiotech.com and we shall get back to you with all the details and project plan.
We undertake end-to-end project management for CAR T-Cell therapy production and distribution. This includes:
1) CAR T laboratory design and GMP guidance
2) CAR T laboratory equipment’s sourcing and supply
3) Production and marketing of CAR T Cell therapy
4) Training for Clinicians, biotechnicians and quality control
5) CD19, CD 22, CD7 and BCMA vector supply
Research and Publications
We have developed over 70 CAR T-cell therapy pipelines. This includes innovative platform technologies such as Boom for dual-specific CAR T cell therapy, YK-Boost for logic-gated CAR T Cell therapy, Bicephali for multi-targeting compound CAR T-Cell therapy, and NKElixir for NK Expression. More than 20 of these therapies have advanced to investigator-initiated clinical (IIT) in China. Our collaborative research has been showcased at prestigious conferences like the Eurpeaon Hematology Association and the American Society of Hematology and over 50 clinical-trial-related papers have been published in top-tier journals.
CAR T Training Program
Equipping Teams for Success in
CAR T Cell Therapy
Modular training programs for hospital teams.
Hands-on workshops for technicians.
Comprehensive clinician training modules covering all aspects of CAR T cell therapy.
Experience & Expertise
China has gained substantial experience and expertise in CAR T cell therapy, showcasing a robust research landscape and significant clinical advancements. In China alone, hospital’s have done more than 6,000 CAR T therapies till date.
Chinese companies and research institutions are leading the development of novel CAR T cell therapies, contributing to the evolution of precision medicine and immunotherapy on a global scale. If you wish to buy CD19 vectors from China, you can write us an email and we will send you complete details.
Collaborations
In recent years, American businesses have begun collaborating with their Chinese counterparts to develop CAR T cell medicines. For ex. In 2015, WuXi AppTec, a Chinese contract research organization (CRO), and Juno Therapeutics, a US-based biopharmaceutical business, partnered strategically. Chinese biopharmaceutical company Cellular Biomedicine Group worked with US biopharmaceutical company Celgene, which is now a division of Bristol-Myers Squibb.
Johnson & Johnson-owned pharmaceutical company Janssen Biotech and Legend Biotech, a company with operations in both China and the US, entered into a global partnership and license agreement.
FAQ’s on CAR T vectors and technology transfer
What are CAR T-cell therapy vectors, and why are they important?
CAR T-cell therapy vectors are specially engineered viral vectors designed to modify a patient’s T-cells to target and destroy specific cancer cells. They are critical in the development of CAR T-cell therapy, a revolutionary treatment for certain cancers like leukemia, lymphoma, auto-immune disorders, and multiple myeloma.
What services do you offer in addition to providing vectors?
We provide comprehensive technology transfer services, including:
Training biotechnicians and clinicians on vector handling, storage, and administration.
Assist with regulatory compliance.
Offering on-site and remote technical support to ensure a seamless CAR T-cell therapy program implementation.
What support do you provide during the implementation of the CAR T-cell therapy program?
Our support includes:
Hands-on training for staff.
Workflow optimization and best practice guidelines.
Ongoing technical assistance to address any challenges that arise.
Regular updates on new advancements in CAR T-cell therapy.
Are there minimum order requirements?
There are no strict minimum order requirements; we cater to the needs of both small and large-scale facilities. However, bulk orders may benefit from cost savings.
Can you help us scale up our CAR T-cell therapy program?
Absolutely. We offer consultancy services to help hospitals and laboratories scale up their CAR T-cell therapy programs and technology transfer, including process optimization, capacity planning, and infrastructure recommendations.
Can you collaborate with us on clinical trials?
Yes, we actively support clinical trials by providing vectors, technical expertise, and regulatory guidance. Please reach out to discuss collaboration opportunities.
What cancer types can be treated with CAR T-Cell therapy using CD19, CD22, CD7 and BCMA vectors?
Our vectors are designed to target:
CD19: Effective against B-cell malignancies such as acute lymphoblastic leukemia (ALL) and diffuse large B-cell lymphoma (DLBCL).
CD22: Used for relapsed/refractory B-cell ALL.
CD7: Targets T-cell malignancies like T-cell acute lymphoblastic leukemia (T-ALL) and peripheral T-cell lymphoma.
BCMA: Specifically designed for multiple myeloma treatment.Can you collaborate with us on clinical trials?
Which CAR T-cell therapy vectors does your company provide?
We specialize in delivering vectors for CD19, CD22, CD7, and BCMA CAR T-cell therapies. These vectors target different antigens, addressing a range of hematological malignancies.
How long does the training program take?
The duration of the training depends on the specific needs of the hospital or laboratory. Typically, our training programs last 3 to 5 days, including hands-on sessions and troubleshooting workshops.
Do you assist with obtaining regulatory approvals for CAR T-cell therapy?
Yes, we guide hospitals and laboratories in preparing documentation and protocols to comply with local and international regulatory requirements.
How quickly can vectors be delivered?
Delivery timelines depend on the location and specific requirements. For standard orders, vectors can typically be delivered within 2-4 weeks.
Are your training programs accredited?
Yes, our training programs are designed to meet international standards and can be tailored to meet the accreditation requirements of your region.
Do you offer any warranties for your products and services?
Yes, we stand by the quality of our products and services. Detailed warranty terms are provided at the time of purchase.
What support do you provide for implementing a CAR T-cell therapy program?
We provide:
Delivery of CD19, CD22, CD7, and BCMA vectors.
Comprehensive training for biotechnicians and clinicians.
Step-by-step guidance for establishing laboratory workflows.
Assistance in quality control and compliance with regulatory standards.
How does your company ensure the quality of the vectors?
Our vectors are manufactured under stringent quality control standards in state-of-the-art facilities, complying with all regulatory requirements. Each batch undergoes rigorous testing to ensure safety, efficacy, and consistency.
Can your vectors be customized for other targets?
Yes, we offer customization services for hospitals and laboratories that require vectors targeting antigens beyond CD19, CD22, CD7, and BCMA. Please contact us with your specific requirements for more details.
What storage conditions are required for your vectors?
We use specialized cryogenic shipping containers to maintain the required temperature throughout transit. Additionally, our logistics team monitors the shipment to ensure timely and safe delivery.
Do you provide troubleshooting support for laboratory processes?
Yes, our experts are available to assist with troubleshooting any technical or operational issues. We provide both on-site and virtual support to address challenges promptly.
How do you ensure the confidentiality of patient and institutional data?
We adhere to strict data protection protocols and comply with all applicable privacy regulations, ensuring that all sensitive information remains confidential.
How can we get started with your services?
To get started, contact us through our website or email (care@beijingbiotech.com), and our team will schedule a consultation to understand your requirements and create a tailored implementation plan.
Can we integrate this therapy into our existing laboratory infrastructure?
Yes, we assess your current setup and provide recommendations or modifications needed to implement CAR T-cell therapy seamlessly.
How long does the technology transfer process take?
Typically, the process takes 6–12 weeks, depending on your facility's preparedness, staff availability, and regulatory approvals.